Montrusco Bolton Investments Inc. Boosts Position in Danaher Corporation (NYSE:DHR)

Montrusco Bolton Investments Inc. raised its stake in Danaher Corporation (NYSE:DHR) by 0.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,716,545 shares of the conglomerate’s stock after buying an additional 719 shares during the quarter. Danaher makes up about 4.5% of Montrusco Bolton Investments Inc.’s investment portfolio, making the stock its 7th largest holding. Montrusco Bolton Investments Inc. owned about 0.24% of Danaher worth $342,587,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Fortis Capital Advisors LLC increased its holdings in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate’s stock valued at $914,000 after purchasing an additional 50 shares during the period. Fayez Sarofim & Co increased its holdings in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock valued at $1,902,000 after purchasing an additional 50 shares during the period. Coastal Bridge Advisors LLC increased its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock valued at $252,000 after purchasing an additional 50 shares during the period. Perennial Investment Advisors LLC increased its holdings in shares of Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 51 shares during the period. Finally, MGO One Seven LLC increased its holdings in shares of Danaher by 1.3% during the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate’s stock valued at $984,000 after purchasing an additional 53 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Leerink Partners raised their price target on Danaher from $225.00 to $230.00 and gave the company an “outperform” rating in a report on Wednesday, April 23rd. Guggenheim reissued a “buy” rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. HSBC dropped their price target on shares of Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Bank of America cut their price target on shares of Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Finally, Wolfe Research cut their price target on shares of Danaher from $275.00 to $220.00 and set an “outperform” rating for the company in a report on Monday, April 7th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $248.43.

Danaher Stock Up 0.3%

Shares of Danaher stock opened at $193.40 on Thursday. The firm has a market cap of $138.41 billion, a price-to-earnings ratio of 37.55, a P/E/G ratio of 2.71 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The stock has a 50-day simple moving average of $196.12 and a 200-day simple moving average of $205.72.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.66%. Danaher’s payout ratio is 24.85%.

Insider Activity at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares of the company’s stock, valued at $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.